Probenecid

Probenecid
Clinical data
Trade names	Probalan
AHFS/Drugs.com	Monograph
MedlinePlus	a682395
Routes of; administration	By mouth
ATC code	M04AB01 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	75-95%
Elimination half-life	2-6 hours (dose: 0.5-1 g)
Excretion	kidney (77-88%)
Identifiers
	IUPAC name 4-(dipropylsulfamoyl)benzoic acid;
CAS Number	57-66-9 ;
PubChem CID	4911;
IUPHAR/BPS	4357;
DrugBank	DB01032 ;
ChemSpider	4742 ;
UNII	PO572Z7917;
KEGG	D00475 ;
ChEMBL	ChEMBL897 ;
CompTox Dashboard (EPA)	DTXSID9021188 ;
ECHA InfoCard	100.000.313
Chemical and physical data
Formula	C13H19NO4S
Molar mass	285.36 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=S(=O)(N(CCC)CCC)c1ccc(C(=O)O)cc1;
	InChI InChI=1S/C13H19NO4S/c1-3-9-14(10-4-2)19(17,18)12-7-5-11(6-8-12)13(15)16/h5-8H,3-4,9-10H2,1-2H3,(H,15,16) ; Key:DBABZHXKTCFAPX-UHFFFAOYSA-N ;
	(verify)

Probenecid, also sold under the brand name Probalan, is a medication that increases uric acid excretion in the urine. It is primarily used in treating gout and hyperuricemia.

Probenecid was developed as an alternative to caronamide^[1] to competitively inhibit renal excretion of some drugs, thereby increasing their plasma concentration and prolonging their effects.

^ Mason RM (June 1954). "Studies on the effect of probenecid (benemid) in gout". Annals of the Rheumatic Diseases. 13 (2): 120–130. doi:10.1136/ard.13.2.120. PMC 1030399. PMID 13171805.

[pmid13171805-1] Mason RM (June 1954). "Studies on the effect of probenecid (benemid) in gout". Annals of the Rheumatic Diseases. 13 (2): 120–130. doi:10.1136/ard.13.2.120. PMC 1030399. PMID 13171805.

[1]

Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.

Probenecid

Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.